Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • News
  • FDA declines to approve Summit’s ivonescimab in lung cancer
  • News

FDA declines to approve Summit’s ivonescimab in lung cancer

The FDA declined to approve Summit's ivonescimab in advanced NSCLC, approved AstraZeneca's Imfinzi with enfortumab vedotin in MIBC, and Seawolf raised $100M alongside a Sanofi partnership worth up to $1.2 billion.
pharminent November 16, 2026

Pharminent · Daily Brief
November 16, 2026

Regulatory & Approvals

FDA declines to approve Summit’s ivonescimab in lung cancer
The US FDA has declined to approve Summit Therapeutics’ biologics license application for ivonescimab in patients with locally advanced or metastatic non-small cell lung cancer.
Pharmaceutical Technology →

FDA approves AstraZeneca’s Imfinzi with enfortumab vedotin in MIBC
The US FDA approved AstraZeneca’s Imfinzi in combination with enfortumab vedotin for adult patients with muscle-invasive bladder cancer who cannot receive or have refused cisplatin-based chemotherapy.
Pharmaceutical Technology →$AZN

Alexion’s Klygefa approved in US and EU for gMG
AstraZeneca’s Alexion unit won approval in the US and the EU for Klygefa in generalised myasthenia gravis.
Pharmaphorum →$AZN

Business & Finance

Seawolf raises $100M and discloses Sanofi partnership
DNA therapeutics developer Seawolf Therapeutics raised $100 million from backers including Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm, and disclosed a partnership with Sanofi worth up to $1.2 billion.
BioPharma Dive →$LLY$NVS$SNY

Oyster Therapeutics raises $60M for tau-degrading small molecules
Oyster Therapeutics raised $60 million in a financing that included Eli Lilly; its lead program is a brain-penetrant small molecule that degrades pathological tau associated with Alzheimer’s disease.
MedCity News →$LLY

Forwarded this? Get your copy free
Sign up free →

Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.

Post navigation

Previous: Lilly Wins China Approval for Oral GLP-1 Weight Loss Drug

Related Stories

  • News

Lilly Wins China Approval for Oral GLP-1 Weight Loss Drug

pharminent November 13, 2026
  • News

Blackstone to fund Pfizer’s monthly GLP-1 with up to $1.5B

pharminent November 12, 2026
  • News

Beam’s base editing sickle cell therapy meets pivotal trial goal

pharminent November 11, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.